Stellantis Streamlines Portfolio Pivots to Four Core Brands in FaSTLAne 2030 Plan Chancellor Rachel Reeves Launches Campaign to Remain in Post Under New Labour Leadership Micron Technology Shares Surge Toward Best Monthly Performance Since 1987 Analysts Continue to See Value US Consumer Prices Rise 38 in April Exceeding Expectations and Hitting Highest Since May 2023 ByteDance Reportedly Poised to Spend Up to 89 Billion in AI Expansion Morgan Stanley Maintains Bullish Stance on NextEra Energy Following Price Target Reduction FITBM Q1 2026 Earnings Preferred Stock Delivers 35 EPS Surprise Above Consensus CNXC Q1 2026 Earnings EPS Misses Estimates as Revenue Growth Remains Uncertain VINP Q1 2026 Earnings EPS Misses Estimates Stock Declines PAG Q1 2026 Earnings EPS Beats Estimates Stock Rises AVAV Q1 2026 Earnings EPS Misses Estimates but Stock Rises on Strategic Outlook GFS Q1 2026 Earnings EPS Surprises to the Upside Amid Strategic Cost Discipline Select Water Solutions WTTR Holds Steady at 1928 Key Levels in Focus Flutter Entertainment FLUT Holds Steady Near Support Following Modest Uptick Roman DBDR Acquisition Corp II Unit DRDBU Holds Steady at 1052 as Support Levels Are Tested Ibotta Inc IBTA Edges Higher as Shares Test Resistance Zone Gaia Inc GAIA Edges Higher Amid Modest Trading Activity RBIs Rate Cut May Signal Shift in Monetary Policy Framework Nomura Suggests SYM Q1 2026 Earnings EPS Misses Estimates but Stock Gains 6 Amid Optimism Tootsie Roll Industries TR Holds Steady Near Support as Confectionary Sector Shows Resilience DNUT Q1 2026 Earnings EPS Misses Estimates as Cost Pressures Weigh on Performance Rapid7 RPD Q1 2026 Earnings EPS Surprises 1765 Above Estimates Shares Rise HD Q1 2026 Earnings EPS Misses Estimates as Stock Rises on Resilient Demand GDS Holdings Q1 2026 Earnings Stunning EPS Beat of 132 vs Expected Loss DAVE Q1 2026 Earnings EPS Beats Estimates by 37 Stock Declines on Lack of Revenue Details Baidu Q1 2026 Earnings EPS Beats Estimates Amid Mixed Market Sentiment CG Oncology Q1 2026 Earnings WiderthanExpected Loss as ClinicalStage Biotech Continues Investment